실적분석 2026년 8월 12일

Lumexa Imaging Holdings ($LMRI) Q2 2026 Earnings Analysis — Adjusted EPS Significantly Beats Expectations; Full-Year Guidance Reiterated

Earnings Scorecard

Revenue: $264.2 million (year-over-year +5.1%, estimate $263 million) ✅ Beat

EPS: Adjusted $0.20 (estimate $0.14) ✅ Beat

Guidance: Reiterated — full-year revenue $1.045–1.097 billion and adjusted EPS $0.71–$0.77 reaffirmed; adjusted EBITDA midpoint of $238 million maintained (range only narrowed)

Stock Reaction: Extended hours +1.53% ($11.91) — as of 06:05 KST on 08-13

Positives

Adjusted EPS Beat: Adjusted $0.20 significantly outpaced the estimate of $0.14

Return to Profitability: Net income of approximately $2.7 million, swinging from a loss in the prior-year period

Advanced Imaging Growth: Consolidated advanced imaging volume +6.8%, with same-center volume +5.2%

The company operates more than 190 outpatient imaging centers nationwide, and expansion of the advanced imaging mix centered on MRI and CT, along with joint ventures and new center ramp-ups, served as the earnings backbone. Year-to-date announcements of four new centers and joint ventures with orthopedic specialty hospitals support the growth narrative.

Negatives

EBITDA Stagnation: Adjusted EBITDA of $56.4 million was roughly flat versus the prior year

Margin Compression: Adjusted EBITDA margin of 21.4% declined from 22.4% a year earlier

No Guidance Upgrade: Full-year revenue and adjusted EPS guidance was merely reiterated

Revenue and earnings came in modestly above expectations, but the pace of profitability improvement was sluggish, and public-company costs (approximately $7 million reflected) are weighing on growth. If the rise in general and administrative expenses and margin pressure persist, additional upside catalysts for the stock could weaken.

What Management Said

Management highlighted same-center growth, an increasing share of advanced imaging, and the ramp-up of new centers as the core drivers of Q2 momentum. Full-year revenue and adjusted EPS guidance was left unchanged, with only the adjusted EBITDA range narrowed — a message that emphasizes execution stability over aggressive upgrades.

Market Reaction and What to Watch Next

The sizable adjusted EPS beat was a positive, but with EBITDA stagnation, margin contraction, and a reiterated guidance all combined, the reaction appears to have been capped at a modest gain.

Whether same-center advanced imaging volume growth is sustained through the second half.

Whether the adjusted EBITDA margin recovers and how much of the public-company cost burden is absorbed.

Whether new centers and joint venture ramp-ups translate into revenue and earnings growth, to be validated by next quarter's results.